BMY/Ipilimumab: As previously noted, I think the OS data for the three arms trump the PFS and RR data that you posted in bold-faced text.
When OS is the secondary endpoint in a cancer trial, one can debate how consequential OS is relative to the primary endpoint and other secondary endpoints. However, when OS is the primary endpoint in a cancer trial, as is the case in the Ipilimumab trial, then good OS data trump anything suboptimal or curious in secondary efficacy endpoints such as PFS and RR.
Moreover, in an indication such as second-line metastatic melanoma, where death comes quickly for many, safety issues are subsumed into the OS measurement and have little standing in their own right.
Market Data 
Markets 
AI
